Kura Oncology Inc
Closed
SectorHealthcare
11.52 -4.64
Overview
Share price change
24h
Min
11.42
Max
12.03
Income | 5M -68M |
|---|---|
Sales | 2.6M 21M |
EPS | -0.77 |
Profit margin | -327.331 |
Employees | 260 |
EBITDA | 7M -66M |
Next Earnings | 3 Nov 2026 |
|---|
Market Cap | 304M 1.2B |
|---|---|
Previous open | 16.16 |
Previous close | 11.52 |
News Sentiment
By Acuity
19%
81%
26 / 339 Healthcare
Kura Oncology Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Kura Oncology Inc Forecast
Sentiment
By Acuity
26 / 339 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.